Display options
Cite
Bourgeois H, Turpin F, Bouchada M, et al. Mitomycin-vinorelbine as second line chemotherapy in metastatic breast cancer . Bull Cancer. 1998;85(9):794
Bourgeois, H., Turpin, F., Bouchada, M., Volters, A., Cvitkovic, F., Goupil, A., Janvier, M., Tubiana-Hulin, M., Soulie, P., Berlie, J., Girard, M., & Rouesse, J. (1998). Mitomycin-vinorelbine as second line chemotherapy in metastatic breast cancer . Bulletin du cancer, 85(9), 794.
Bourgeois, et al. "Mitomycin-vinorelbine as second line chemotherapy in metastatic breast cancer ." Bulletin du cancer vol. 85,9 (1998): 794.
Bourgeois H, Turpin F, Bouchada M, Volters A, Cvitkovic F, Goupil A, Janvier M, Tubiana-Hulin M, Soulie P, Berlie J, Girard M, Rouesse J. Mitomycin-vinorelbine as second line chemotherapy in metastatic breast cancer . Bull Cancer. 1998 Sep;85(9):794. PMID: 9770603.
Copy Download .nbib Format: NLM
Share it on

Bull Cancer. 1998 Sep;85(9):794.

Mitomycin-vinorelbine as second line chemotherapy in metastatic breast cancer .

Bulletin du cancer

Bourgeois, Turpin, Bouchada, Volters, Cvitkovic, Goupil, Janvier, Tubiana-Hulin, Soulie, Berlie, Girard, Rouesse

PMID: 9770603

Abstract

Fourty-six patients (41 evaluable) were treated in second line chemotherapy of metastatic breast cancer (MBC) by an association of mitomycin (M), vinorelbine (V) (M 8 mg/m2 D1, V 25 mg/m2 D1 and DI 8 every 4 weeks). Median age was 58 years (36-78), median performance status 1 (0-3). Thirty-seven per cent of the tumors were estrogen receptors positive and 17% progesterone receptors positive.eventeen patients received an adjuvant chemotherapy and 39 a first line chemotherapy with anthracyclin (A). The median number of metastatic sites was 2 (1-4) and 27 patients (67%) had visceral metastases. Twelve patients were refractory to anthracyclins and 5 resistant. No toxic death nor hemolytic uremic syndrom were observed.even (3,7%) febrile neutropenias happened responsible for 4 hospitalizations. A grade 3 or 4 neutropenia was noted in 34% of the cycles but no other clinic toxicity nor grade 3 or 4 thrombopenia. The rate of objective response (OR) was 37,5% with 2 complete responses (CR) and 13 partial responses (PR).even patients had stable disease and 18 progressed. The rate of hepatic OR was 31%. Five (40%) A-refractory patients responded but no resistant patient. Median OR time was 10 weeks (8-12) and median OR duration was 5 months (3-6). Median survival was 11,5 months. MV association is well tolerated and effective in second line chemotherapy for MBC even with hepatic metastasis and in patients refractory to anthracyclins.

Publication Types